Fully Automated Tissue Perfusion Estimation Using Ultrasound: Application in Human Placenta



Yi YIN^{1,2}, Alys CLARK³, and Sally COLLINS^{1,4}

- ¹ Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK
- ² Big Data Institute, University of Oxford, Oxford, UK
- ³ Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand
- ⁴ Fetal Medicine Unit, the Women's Centre, John Radcliffe Hospital, Oxford, UK

Introduction

Background: power Doppler ultrasound (PD-US) is the ideal modality to assess tissue perfusion as it is cheap, patient-friendly and does not require ionizing radiation. However, meaningful inter-patient comparison only occurs if differences in tissue-attenuation are corrected for.







Power doppler ultrasound

Objective: propose a fully automated method named **3D-svFMBV** (3D Signal Vessel Fractional Moving Blood Volume) to standardise the PD signals to correct the attenuation [1].

Clinical utility: evaluate 3D-svFMBV using 143 first-trimester placental ultrasound volumes. More biologically plausible perfusion estimates were obtained, showing improved prediction of pre-eclampsia compared with the results of the old technique FMBV [2].

Uterine vasculature in pregnancy [4]



Standardisation value (PD signal)

tissue divided by the obtained

standardization value.

3D-svFMBV *

calculated from this reference vessel

• Average PD signal values within the target

- fetus to localize placental bed
- Two pathway, hybrid Model using **Transfer Learning**
- Achieve the state-of-the-art performance, Dice similarity coefficient (**DSC**): 0.82 (0.08) for placenta, 0.93 (0.04) for amniotic fluid, 0.88 (0.04) for fetus



Scheme of 3D-svFMBV estimation: the processing pipeline shows the steps to estimate 3D-svFMBV values at placental bed.

Results









Clinical data:

- A total of 143 women underwent scanning between 11+0 and 13+6 weeks' gestation. The pregnancy outcomes were collected from the hospital records
- 3D-US data were collected as part of a previous study with ethical approval for secondary analysis (REC ref: 08/H0604/163).
- Scans were acquired using a Voluson E8[™] (GE Healthcare, Milwaukee, USA) scanner and a RAB4-8-



- This has the potential to serve as a screening test for adverse pregnancy outcomes.
- The proposed perfusion estimation has the potential to be used for many different target organs e.g. ovary, kidney, and tumor perfusion.

*Contact: yi.yin@wrh.ox.ac.uk

[5] Pádraig Looney et al., IEEE Transactions on UFFC, 2021

[4] Alys Clark et al., Placenta, Volume 66, 2018